What is the recommended dosing regimen for Marinol (dronabinol) for appetite stimulation in HIV/AIDS patients and for chemotherapy‑induced nausea and vomiting?

Marinol Dosing

For appetite stimulation in HIV/AIDS patients, start Marinol at 2.5 mg orally twice daily (one hour before lunch and dinner), with a maximum dose of 10 mg twice daily; for chemotherapy-induced nausea and vomiting, start at 5 mg/m² orally 1-3 hours before chemotherapy, then every 2-4 hours after chemotherapy for 4-6 doses per day, with a maximum of 15 mg/m² per dose. 1

Appetite Stimulation in HIV/AIDS Patients

Starting Regimen

• Standard dose: 2.5 mg orally twice daily, administered one hour before lunch and one hour before dinner 1
• Elderly or intolerant patients: Consider 2.5 mg once daily, one hour before dinner or at bedtime to minimize CNS adverse effects 1

Dose Titration

If the patient tolerates the initial dose and requires additional therapeutic effect:

• Increase gradually to 2.5 mg before lunch and 5 mg before dinner 1
• Most patients respond adequately to 2.5 mg twice daily 1
• If needed, further increase to 5 mg before lunch and 5 mg before dinner 1
• Maximum dose: 10 mg twice daily 1

Clinical Evidence

Research demonstrates that dronabinol 2.5 mg twice daily significantly increases appetite (38% vs 8% for placebo, p=0.015), stabilizes weight, and improves mood in AIDS patients with anorexia 2. A smaller study using 5 mg twice daily showed increased body fat percentage and trends toward weight gain 3.

Chemotherapy-Induced Nausea and Vomiting

Starting Regimen

• Standard dose: 5 mg/m² orally, administered 1-3 hours before chemotherapy 1
• Maintenance: Continue every 2-4 hours after chemotherapy for a total of 4-6 doses per day 1
• Elderly patients: Consider starting at 2.5 mg/m² once daily, 1-3 hours before chemotherapy 1

Administration Timing

• Take the first dose on an empty stomach at least 30 minutes before eating 1
• Subsequent doses can be taken with or without food 1
• Maintain consistent timing relative to meals throughout each chemotherapy cycle 1

Dose Titration

• Increase in increments of 2.5 mg/m² based on clinical response 1
• Maximum dose: 15 mg/m² per dose for 4-6 doses per day 1
• If CNS adverse effects occur, consider reducing to 2.5 mg once daily 1-3 hours before chemotherapy 1

Guideline Context

The 2024 ASCO guideline on cannabis and cannabinoids notes moderate-quality evidence for dronabinol in chemotherapy-induced nausea and vomiting 4. However, older ASCO (2011) and ESMO (2005) antiemetic guidelines do not include cannabinoids in their primary recommendations, focusing instead on 5-HT3 antagonists, NK1 antagonists, and corticosteroids 5, 6. This reflects that Marinol is reserved for patients who have failed conventional antiemetic treatments 1.

Clinical Evidence

Combination therapy with dronabinol 10 mg every 6 hours plus prochlorperazine 10 mg every 6 hours was significantly more effective than either agent alone, with only 29% experiencing nausea versus 47% with dronabinol alone and 60% with prochlorperazine alone 7. Meta-analyses confirm cannabinoids are more effective than placebo for preventing both nausea and vomiting, though evidence is limited by older comparator regimens 8, 9.

Important Safety Considerations

CNS Adverse Effects

• Dose-related: euphoria, dizziness, confusion, somnolence, dysphoria, and paranoid reactions 1
• Most CNS effects resolve within 1-3 days and typically don't require dose reduction 1
• If severe or persistent, reduce to 2.5 mg in the evening or at bedtime 1
• Elderly patients are particularly sensitive to neuropsychiatric effects 1

Contraindications and Precautions

• Contraindicated in patients with hypersensitivity to dronabinol or sesame oil 1
• Screen for psychiatric history (mania, depression, schizophrenia) before initiating 1
• Monitor patients with heart problems for blood pressure changes and falls 1
• Avoid in pregnancy; discontinue breastfeeding during treatment and for 9 days after last dose for CINV indication 1

Drug Interactions

Marinol is metabolized via CYP3A4 and CYP2C9, requiring caution with medications affecting these pathways 1. Avoid concomitant use with other drugs causing similar psychiatric effects 1.

Abuse Potential

Marinol is a Schedule III controlled substance due to dronabinol content 1. Monitor for abuse behaviors, particularly in patients with history of drug or alcohol dependence 1.